Dbv Technologies Debt 2024

Dbv Technologies Aktienanalyse

What does Dbv Technologies do?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Dbv Technologies's Debt Structure

Dbv Technologies's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Dbv Technologies's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Dbv Technologies’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Dbv Technologies’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Dbv Technologies Stock

What is the debt of Dbv Technologies this year?

Dbv Technologies has a debt level of -135.7 USD this year.

What was the debt of Dbv Technologies compared to the previous year?

The debt of Dbv Technologies has increased by -34.18% compared to the previous year dropped.

What are the consequences of high debt for investors in Dbv Technologies?

High debt can pose a risk for investors of Dbv Technologies, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Dbv Technologies?

Low debt means that Dbv Technologies has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Dbv Technologies affect the company?

An increase in debt of Dbv Technologies can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Dbv Technologies affect the company?

A reduction in debt of Dbv Technologies can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Dbv Technologies?

Some factors that can influence the debt of Dbv Technologies include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Dbv Technologies so important for investors?

The debts of Dbv Technologies are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Dbv Technologies take to change the debt?

To change the debt, Dbv Technologies can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Dbv Technologies pay?

Over the past 12 months, Dbv Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dbv Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Dbv Technologies?

The current dividend yield of Dbv Technologies is .

When does Dbv Technologies pay dividends?

Dbv Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dbv Technologies?

Dbv Technologies paid dividends every year for the past 0 years.

What is the dividend of Dbv Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dbv Technologies located?

Dbv Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dbv Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dbv Technologies from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Dbv Technologies pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Dbv Technologies in the year 2023?

In the year 2023, Dbv Technologies distributed 0 USD as dividends.

In which currency does Dbv Technologies pay out the dividend?

The dividends of Dbv Technologies are distributed in USD.